Rapid Blood-Pressure Lowering in Patients with Acute Intracerebral Hemorrhage
Craig S Anderson, Emma Heeley, Yining Huang, Jiguang Wang, Christian Stapf, Candice Delcourt, Richard Lindley, Thompson Robinson, Pablo Lavados, Bruce Neal, Jun Hata, Hisatomi Arima, Mark Parsons, Yuechun Li, Jinchao Wang, Stephane Heritier, Qiang Li, Mark Woodward, R John Simes, Stephen M Davis Show all
NEW ENGLAND JOURNAL OF MEDICINE | MASSACHUSETTS MEDICAL SOC | Published : 2013
BACKGROUND: Whether rapid lowering of elevated blood pressure would improve the outcome in patients with intracerebral hemorrhage is not known. METHODS: We randomly assigned 2839 patients who had had a spontaneous intracerebral hemorrhage within the previous 6 hours and who had elevated systolic blood pressure to receive intensive treatment to lower their blood pressure (with a target systolic level of <140 mm Hg within 1 hour) or guideline-recommended treatment (with a target systolic level of <180 mm Hg) with the use of agents of the physician's choosing. The primary outcome was death or major disability, which was defined as a score of 3 to 6 on the modified Rankin scale (in which a score..View full abstract
Awarded by National Health and Medical Research Council (NHMRC) of Australia
Funded by the National Health and Medical Research Council of Australia; INTERACT2 ClinicalTrials.gov number, NCT00716079.Supported by a program grant (571281), project grants (512402 and 1004170), a Senior Principal Research Fellowship (to Dr. Anderson), and a Principal Research Fellowship (to Dr. Neal) from the National Health and Medical Research Council (NHMRC) of Australia. Drs. Neal, Arima, and Parsons are recipients of Future Fellowships from the Australian Research Council. Dr. Hata is a recipient of a Postgraduate Fellowship from the High Blood Pressure Research Council of Australia.Dr. Huang reports receiving reimbursement for travel expenses from Osaka Pharmaceuticals; Dr. Jiguang Wang, receiving consulting fees from Novartis, Omron Healthcare, Pfizer, and Takeda, grant support from Novartis, Omron Healthcare, and Pfizer, lecture fees from A&D Pharma, Omron Healthcare, Novartis, Pfizer, and Servier, and reimbursement for travel expenses from Pfizer and Takeda; Dr. Lavados, receiving grant support from Lundbeck, payment for manuscript preparation from BMJ, and payment for advisory board membership from Bristol-Myers Squibb; and Dr. Davis, receiving lecture fees from Boehringer Ingelheim, Sanofi-Aventis, and EVER Neuro Pharma. No other potential conflict of interest relevant to this article was reported.